Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Long‐term survival of a patient with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) and untreated multiple brain metastases treated with zorifertinib: A case report

“…She achieved PR in both extra‐ and intracranial tumor lesions, developed EGFR T790M mutation after PD on zorifertinib, and finally achieved an OS of more than 65 months. The AEs with zorifertinib were consistent with those reported in phase 1–3 studies and other EGFR‐TKIs 10,12,13 …”

“… 10 , 18 In previous studies, first‐line zorifertinib was particularly effective in controlling BM (extracranial PD is the main pattern of PD), and the main acquired resistance mutation was EGFR T790M which is subsequently treatable with third‐generation EGFR‐TKIs, helping to prolong OS of patients; the median OS was 34.1 months in patients subsequently treated with osimertinib in CTONG1702, and is consistent with that of the phase 3 EVEREST study (data on file). 12 , 13 …”

“…The AEs with zorifertinib were consistent with those reported in phase 1–3 studies and other EGFR‐TKIs. 10 , 12 , 13 …”

“…Zorifertinib (AZD3759), a novel EGFR‐TKI inhibiting mutant EGFR (exon 19del or L858R), is not a substrate of either P‐glycoprotein or breast cancer resistance protein and was designed specifically to improve blood–brain barrier (BBB) penetration 10,11 and to treat EGFR ‐mutant NSCLC patients with BM. In phase 1–3 studies, zorifertinib has shown promising antitumor activity 10,12,13 …”